<?xml version="1.0" encoding="utf-8"?>
<TEI xmlns="http://www.tei-c.org/ns/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:hal="http://hal.archives-ouvertes.fr/" xmlns:gml="http://www.opengis.net/gml/3.3/" xmlns:gmlce="http://www.opengis.net/gml/3.3/ce" version="1.1" xsi:schemaLocation="http://www.tei-c.org/ns/1.0 http://api.archives-ouvertes.fr/documents/aofr-sword.xsd">
  <teiHeader>
    <fileDesc>
      <titleStmt>
        <title>HAL TEI export of hal-04591309</title>
      </titleStmt>
      <publicationStmt>
        <distributor>CCSD</distributor>
        <availability status="restricted">
          <licence target="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0 - Universal</licence>
        </availability>
        <date when="2026-05-10T19:28:37+02:00"/>
      </publicationStmt>
      <sourceDesc>
        <p part="N">HAL API Platform</p>
      </sourceDesc>
    </fileDesc>
  </teiHeader>
  <text>
    <body>
      <listBibl>
        <biblFull>
          <titleStmt>
            <title xml:lang="en">Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE study</title>
            <author role="aut">
              <persName>
                <forename type="first">Patrick</forename>
                <surname>Henry</surname>
              </persName>
              <email type="md5">8da2cd72487e428b1d81bef406051927</email>
              <email type="domain">aphp.fr</email>
              <idno type="idhal" notation="numeric">1340635</idno>
              <idno type="halauthorid" notation="string">152925-1340635</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-9544-5031</idno>
              <affiliation ref="#struct-300128"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Bertrand</forename>
                <surname>Cariou</surname>
              </persName>
              <email type="md5">1eed1f2b671cbc31cf91c6a2af157d87</email>
              <email type="domain">univ-nantes.fr</email>
              <idno type="idhal" notation="numeric">761594</idno>
              <idno type="halauthorid" notation="string">410249-761594</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-1580-8040</idno>
              <idno type="IDREF">https://www.idref.fr/075934981</idno>
              <affiliation ref="#struct-474972"/>
              <affiliation ref="#struct-1088523"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Michel</forename>
                <surname>Farnier</surname>
              </persName>
              <email type="md5">fcd2a50bfac9a03a9eb8eea8399bcb88</email>
              <email type="domain">orange.fr</email>
              <idno type="idhal" notation="numeric">1465502</idno>
              <idno type="halauthorid" notation="string">1143870-1465502</idno>
              <idno type="ORCID">https://orcid.org/0000-0002-0349-7978</idno>
              <idno type="IDREF">https://www.idref.fr/063055295</idno>
              <affiliation ref="#struct-477904"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Sarah</forename>
                <forename type="middle">L</forename>
                <surname>Lakhdari</surname>
              </persName>
              <idno type="halauthorid">3159494-0</idno>
              <affiliation ref="#struct-1136266"/>
            </author>
            <author role="aut">
              <persName>
                <forename type="first">Bruno</forename>
                <surname>Detournay</surname>
              </persName>
              <email type="md5">7a203b491b82f568461f70e27b423aac</email>
              <email type="domain">cemka.fr</email>
              <idno type="idhal" notation="numeric">1386559</idno>
              <idno type="halauthorid" notation="string">706068-1386559</idno>
              <affiliation ref="#struct-1062252"/>
            </author>
            <editor role="depositor">
              <persName>
                <forename>Catherine</forename>
                <surname>Vergely</surname>
              </persName>
              <email type="md5">2b2bf1371e5dc70fdab3a4533729bf13</email>
              <email type="domain">u-bourgogne.fr</email>
            </editor>
          </titleStmt>
          <editionStmt>
            <edition n="v1" type="current">
              <date type="whenSubmitted">2024-05-28 16:59:57</date>
              <date type="whenModified">2026-04-29 08:24:01</date>
              <date type="whenReleased">2024-05-31 11:16:07</date>
              <date type="whenProduced">2022-12-09</date>
              <date type="whenEndEmbargoed">2024-05-28</date>
              <ref type="file" target="https://ube.hal.science/hal-04591309v1/document">
                <date notBefore="2024-05-28"/>
              </ref>
              <ref type="file" subtype="greenPublisher" n="1" target="https://ube.hal.science/hal-04591309v1/file/1-s2.0-S187521362200225X-main.pdf" id="file-4591309-3983609">
                <date notBefore="2024-05-28"/>
              </ref>
            </edition>
            <respStmt>
              <resp>contributor</resp>
              <name key="176992">
                <persName>
                  <forename>Catherine</forename>
                  <surname>Vergely</surname>
                </persName>
                <email type="md5">2b2bf1371e5dc70fdab3a4533729bf13</email>
                <email type="domain">u-bourgogne.fr</email>
              </name>
            </respStmt>
          </editionStmt>
          <publicationStmt>
            <distributor>CCSD</distributor>
            <idno type="halId">hal-04591309</idno>
            <idno type="halUri">https://ube.hal.science/hal-04591309</idno>
            <idno type="halBibtex">henry:hal-04591309</idno>
            <idno type="halRefHtml">&lt;i&gt;Archives of cardiovascular diseases&lt;/i&gt;, 2022, 116 (1), pp.3 - 8. &lt;a target="_blank" href="https://dx.doi.org/10.1016/j.acvd.2022.10.004"&gt;&amp;#x27E8;10.1016/j.acvd.2022.10.004&amp;#x27E9;&lt;/a&gt;</idno>
            <idno type="halRef">Archives of cardiovascular diseases, 2022, 116 (1), pp.3 - 8. &amp;#x27E8;10.1016/j.acvd.2022.10.004&amp;#x27E9;</idno>
            <availability status="restricted">
              <licence target="https://about.hal.science/hal-authorisation-v1/">HAL Authorization<ref corresp="#file-4591309-3983609"/></licence>
            </availability>
          </publicationStmt>
          <seriesStmt>
            <idno type="stamp" n="INSERM">INSERM - Institut national de la santé et de la recherche médicale</idno>
            <idno type="stamp" n="UNIV-BOURGOGNE">Université Bourgogne Europe</idno>
            <idno type="stamp" n="CNRS">CNRS - Centre national de la recherche scientifique</idno>
            <idno type="stamp" n="APHP" corresp="INSERM">AP-HP</idno>
            <idno type="stamp" n="GIP-BE">GIP Bretagne Environnement</idno>
            <idno type="stamp" n="THORAX-UMR">L'unité de recherche de l'institut du thorax (INSERM UMR1087, CNRS UMR6291)</idno>
            <idno type="stamp" n="NANTES-UNIVERSITE">Nantes Université</idno>
            <idno type="stamp" n="NANTES-UNIV">Nantes Université</idno>
            <idno type="stamp" n="PEC2" corresp="UNIV-BOURGOGNE">Physiopathologie et Epidémiologie Cérébro-Cardiovasculaires (PEC2)</idno>
            <idno type="stamp" n="UFR-MEDECINE-NANTES">UFR de médecine - Nantes Université</idno>
          </seriesStmt>
          <notesStmt>
            <note type="audience" n="2">International</note>
            <note type="popular" n="0">No</note>
            <note type="peer" n="1">Yes</note>
          </notesStmt>
          <sourceDesc>
            <biblStruct>
              <analytic>
                <title xml:lang="en">Lipid-lowering efficacy and safety of alirocumab in a real-life setting in France: Insights from the ODYSSEY APPRISE study</title>
                <author role="aut">
                  <persName>
                    <forename type="first">Patrick</forename>
                    <surname>Henry</surname>
                  </persName>
                  <email type="md5">8da2cd72487e428b1d81bef406051927</email>
                  <email type="domain">aphp.fr</email>
                  <idno type="idhal" notation="numeric">1340635</idno>
                  <idno type="halauthorid" notation="string">152925-1340635</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-9544-5031</idno>
                  <affiliation ref="#struct-300128"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Bertrand</forename>
                    <surname>Cariou</surname>
                  </persName>
                  <email type="md5">1eed1f2b671cbc31cf91c6a2af157d87</email>
                  <email type="domain">univ-nantes.fr</email>
                  <idno type="idhal" notation="numeric">761594</idno>
                  <idno type="halauthorid" notation="string">410249-761594</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-1580-8040</idno>
                  <idno type="IDREF">https://www.idref.fr/075934981</idno>
                  <affiliation ref="#struct-474972"/>
                  <affiliation ref="#struct-1088523"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Michel</forename>
                    <surname>Farnier</surname>
                  </persName>
                  <email type="md5">fcd2a50bfac9a03a9eb8eea8399bcb88</email>
                  <email type="domain">orange.fr</email>
                  <idno type="idhal" notation="numeric">1465502</idno>
                  <idno type="halauthorid" notation="string">1143870-1465502</idno>
                  <idno type="ORCID">https://orcid.org/0000-0002-0349-7978</idno>
                  <idno type="IDREF">https://www.idref.fr/063055295</idno>
                  <affiliation ref="#struct-477904"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Sarah</forename>
                    <forename type="middle">L</forename>
                    <surname>Lakhdari</surname>
                  </persName>
                  <idno type="halauthorid">3159494-0</idno>
                  <affiliation ref="#struct-1136266"/>
                </author>
                <author role="aut">
                  <persName>
                    <forename type="first">Bruno</forename>
                    <surname>Detournay</surname>
                  </persName>
                  <email type="md5">7a203b491b82f568461f70e27b423aac</email>
                  <email type="domain">cemka.fr</email>
                  <idno type="idhal" notation="numeric">1386559</idno>
                  <idno type="halauthorid" notation="string">706068-1386559</idno>
                  <affiliation ref="#struct-1062252"/>
                </author>
              </analytic>
              <monogr>
                <idno type="halJournalId" status="VALID">60015</idno>
                <idno type="issn">1875-2136</idno>
                <idno type="eissn">1875-2128</idno>
                <title level="j">Archives of cardiovascular diseases</title>
                <imprint>
                  <publisher>Elsevier ; Société française de cardiologie [2008-....]</publisher>
                  <biblScope unit="volume">116</biblScope>
                  <biblScope unit="issue">1</biblScope>
                  <biblScope unit="pp">3 - 8</biblScope>
                  <date type="datePub">2022-12-09</date>
                </imprint>
              </monogr>
              <idno type="doi">10.1016/j.acvd.2022.10.004</idno>
              <idno type="pubmed">36535853</idno>
            </biblStruct>
          </sourceDesc>
          <profileDesc>
            <langUsage>
              <language ident="en">English</language>
            </langUsage>
            <textClass>
              <keywords scheme="author">
                <term xml:lang="en">Cardiovascular risk</term>
                <term xml:lang="en">France</term>
                <term xml:lang="en">Hypercholesterolaemia</term>
                <term xml:lang="en">PCSK9 inhibitor</term>
                <term xml:lang="en">Real-life study</term>
              </keywords>
              <classCode scheme="halDomain" n="sdv.ee.sant">Life Sciences [q-bio]/Ecology, environment/Health</classCode>
              <classCode scheme="halTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halOldTypology" n="ART">Journal articles</classCode>
              <classCode scheme="halTreeTypology" n="ART">Journal articles</classCode>
            </textClass>
            <abstract xml:lang="en">
              <p>Background: Recently, a multicentre, prospective, single-arm, phase 3b, open-label trial was conducted to determine the safety and efficacy of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in a real-life setting. This study enrolled patients at high cardiovascular risk, with heterozygous familial hypercholesterolaemia (HeFH) or non-familial hypercholesterolaemia (non-FH). Results showed that alirocumab was well tolerated and resulted in a clinically signiﬁcant reduction in low-density lipoprotein cholesterol (LDL-C).Aim: This ancillary analysis aimed to describe the characteristics of the French patients enrolled in the study, the main results observed in this population according to their familial hypercholesterolaemia status, and adherence to treatment.Methods: French data were analysed separately from the original dataset of the study.Results: Among 215 French patients in the ODYSSEY APPRISE trial, 63.7% had non-FH, with a mean LDL-C concentration of 5.0±1.8mmol/L at baseline. The mean duration of alirocumab exposure was 72.4±42.5 weeks, with only 48.4% of patients receiving statins concomitantly. At week 12, a mean reduction in LDL-C of 56.5±17.8% was observed: 51.2±22.8% in HeFH; 59.5±13.2% in non-FH. This improvement in LDL-C started from week 4 and remained stable and sustained until week 120 in both populations. The overall incidence of severe treatment-emergent adverse events (TEAEs) was 33.5%. The most frequent TEAEs were myalgia (15.8%) and asthenia (15.3%). No tolerance or efficacy differences were observed between patients with or without established coronary artery disease or other cardiovascular disease, whatever the age of these events or considering the concomitant use of other lipid-lowering therapies.Conclusions: In the French setting, alirocumab was well tolerated, safe and highly effective at reducing LDL-C. These findings support the use of alirocumab to manage hypercholesterolaemia in patients at high cardiovascular risk.</p>
            </abstract>
          </profileDesc>
        </biblFull>
      </listBibl>
    </body>
    <back>
      <listOrg type="structures">
        <org type="institution" xml:id="struct-300128" status="VALID">
          <orgName>Hôpital Lariboisière-Fernand-Widal [APHP]</orgName>
          <desc>
            <address>
              <addrLine>2, rue Ambroise - Paré 75475</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://hopital-lariboisiere.aphp.fr/</ref>
          </desc>
          <listRelation>
            <relation active="#struct-300068" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-474972" status="VALID">
          <idno type="IdRef">034926445</idno>
          <idno type="ROR">https://ror.org/05c1qsg97</idno>
          <idno type="Wikidata">Q2945767</idno>
          <orgName>Centre Hospitalier Universitaire de Nantes = Nantes University Hospital</orgName>
          <orgName type="acronym">CHU Nantes</orgName>
          <desc>
            <address>
              <addrLine>1 Place Alexis-Ricordeau, 44000 Nantes</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.chu-nantes.fr</ref>
          </desc>
        </org>
        <org type="laboratory" xml:id="struct-1088523" status="VALID">
          <idno type="IdRef">190708026</idno>
          <idno type="RNSR">201220396X</idno>
          <idno type="ROR">https://ror.org/049kkt456</idno>
          <orgName>ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291</orgName>
          <orgName type="acronym">ITX-lab</orgName>
          <date type="start">2022-01-01</date>
          <desc>
            <address>
              <addrLine>8 quai Moncousu - BP 70721 - 44007 Nantes Cedex 1</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.umr1087.univ-nantes.fr/</ref>
          </desc>
          <listRelation>
            <relation name="U1087" active="#struct-303623" type="direct"/>
            <relation name="UMR6291" active="#struct-441569" type="direct"/>
            <relation active="#struct-1088522" type="direct"/>
            <relation active="#struct-1083368" type="indirect"/>
            <relation active="#struct-1083366" type="indirect"/>
          </listRelation>
        </org>
        <org type="laboratory" xml:id="struct-477904" status="OLD">
          <idno type="IdRef">202760278</idno>
          <idno type="RNSR">201722761W</idno>
          <idno type="ROR">https://ror.org/0250h3a52</idno>
          <orgName>Physiopathologie et épidémiologie cérébro-cardiovasculaires [Dijon]</orgName>
          <orgName type="acronym">PEC2</orgName>
          <date type="start">2017-01-01</date>
          <date type="end">2024-12-31</date>
          <desc>
            <address>
              <addrLine>Université de Bourgogne - 21000 Dijon</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://recherche.u-bourgogne.fr/potentiel-de-recherche/laboratoires/physiopathologie-et-epidemiologie-cerebro-cardiovasculaire-pec2.html</ref>
          </desc>
          <listRelation>
            <relation name="EA 7460/UR 7460" active="#struct-300270" type="direct"/>
            <relation active="#struct-426438" type="direct"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-1136266" status="VALID">
          <orgName>Sanofi Gentilly</orgName>
          <orgName type="acronym">Sanofi Gentilly</orgName>
          <date type="start">2022-09-30</date>
          <desc>
            <address>
              <addrLine>82 Avenue Raspail94250 Gentilly</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.sanofi.fr/fr/nous-connaitre/nos-sites-en-france/le-site-tertiaire-du-campus-sanofi-val-de-bievre</ref>
          </desc>
        </org>
        <org type="laboratory" xml:id="struct-1062252" status="INCOMING">
          <orgName>Pôle Real World Evidence [Bourg-la-Reine]</orgName>
          <orgName type="acronym">CEMKA</orgName>
          <desc>
            <address>
              <country key="FR"/>
            </address>
          </desc>
          <listRelation>
            <relation active="#struct-500286" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-300068" status="VALID">
          <idno type="ROR">https://ror.org/00pg5jh14</idno>
          <orgName>Assistance publique - Hôpitaux de Paris (AP-HP)</orgName>
          <orgName type="acronym">AP-HP</orgName>
          <desc>
            <address>
              <country key="FR"/>
            </address>
          </desc>
        </org>
        <org type="institution" xml:id="struct-303623" status="VALID">
          <idno type="IdRef">026388278</idno>
          <idno type="ROR">https://ror.org/02vjkv261</idno>
          <orgName>Institut National de la Santé et de la Recherche Médicale</orgName>
          <orgName type="acronym">INSERM</orgName>
          <desc>
            <address>
              <addrLine>101, rue de Tolbiac, 75013 Paris</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.inserm.fr</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-441569" status="VALID">
          <idno type="IdRef">02636817X</idno>
          <idno type="ISNI">0000000122597504</idno>
          <idno type="ROR">https://ror.org/02feahw73</idno>
          <orgName>Centre National de la Recherche Scientifique</orgName>
          <orgName type="acronym">CNRS</orgName>
          <date type="start">1939-10-19</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.cnrs.fr/</ref>
          </desc>
        </org>
        <org type="regrouplaboratory" xml:id="struct-1088522" status="VALID">
          <idno type="IdRef">076954927</idno>
          <orgName>Nantes Université - UFR de Médecine et des Techniques Médicales</orgName>
          <orgName type="acronym">Nantes Univ - UFR MEDECINE</orgName>
          <date type="start">2022-01-01</date>
          <desc>
            <address>
              <addrLine>1 rue Gaston Veil BP 53508 44035 NANTES Cedex 1</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.medecine.univ-nantes.fr</ref>
          </desc>
          <listRelation>
            <relation active="#struct-1083368" type="direct"/>
            <relation active="#struct-1083366" type="indirect"/>
          </listRelation>
        </org>
        <org type="institution" xml:id="struct-1083368" status="VALID">
          <orgName>Nantes Université - pôle Santé</orgName>
          <date type="start">2022-01-01</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
            <ref type="url">https://nouvelleuniversite.univ-nantes.fr/les-poles</ref>
          </desc>
          <listRelation>
            <relation active="#struct-1083366" type="direct"/>
          </listRelation>
        </org>
        <org type="regroupinstitution" xml:id="struct-1083366" status="VALID">
          <idno type="IdRef">258086599</idno>
          <idno type="ROR">https://ror.org/03gnr7b55</idno>
          <orgName>Nantes Université</orgName>
          <orgName type="acronym">Nantes Univ</orgName>
          <date type="start">2022-01-01</date>
          <desc>
            <address>
              <country key="FR"/>
            </address>
          </desc>
        </org>
        <org type="institution" xml:id="struct-300270" status="OLD">
          <idno type="IdRef">02819005X</idno>
          <idno type="ISNI">0000000122989313</idno>
          <idno type="ROR">https://ror.org/03k1bsr36</idno>
          <orgName>Université de Bourgogne</orgName>
          <orgName type="acronym">UB</orgName>
          <date type="end">2024-12-31</date>
          <desc>
            <address>
              <addrLine>Maison de l'université - Esplanade Érasme - BP 27877 - 21078 Dijon cedex</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.u-bourgogne.fr/</ref>
          </desc>
        </org>
        <org type="regroupinstitution" xml:id="struct-426438" status="VALID">
          <idno type="IdRef">200716271</idno>
          <idno type="ISNI">0000 0004 4910 6615</idno>
          <idno type="ROR">https://ror.org/02dn7x778</idno>
          <orgName>Université Bourgogne Franche-Comté [COMUE]</orgName>
          <orgName type="acronym">UBFC</orgName>
          <date type="start">2015-04-01</date>
          <date type="end">2024-12-31</date>
          <desc>
            <address>
              <addrLine>32, avenue de l’observatoire25000 BESANCON</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">http://www.ubfc.fr</ref>
          </desc>
        </org>
        <org type="institution" xml:id="struct-500286" status="VALID">
          <idno type="ISNI">0000 0004 0640 5009</idno>
          <idno type="ROR">https://ror.org/006fc7318</idno>
          <orgName>Cemka-eval</orgName>
          <date type="start">1990-01-01</date>
          <desc>
            <address>
              <addrLine>43, Boulevard du Maréchal Joffre – 92340 Bourg-La-Reine.</addrLine>
              <country key="FR"/>
            </address>
            <ref type="url">https://www.cemka.fr/</ref>
          </desc>
        </org>
      </listOrg>
    </back>
  </text>
</TEI>